Hedy Kindler to Pyridines
This is a "connection" page, showing publications Hedy Kindler has written about Pyridines.
Connection Strength
1.190
-
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
Score: 0.447
-
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6.
Score: 0.342
-
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer. 2004 Aug; 45 Suppl 1:S125-7.
Score: 0.205
-
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
Score: 0.078
-
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6.
Score: 0.078
-
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
Score: 0.030
-
Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103.
Score: 0.010